Transpara vs DeepHealth

Direct competitors — feature-level head-to-head below. Comparability 85/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Transpara

by ScreenPoint Medical

DeepHealth

by RadNet, Inc.

AI Verdict

Transpara and DeepHealth are direct competitors in the realm of AI-powered breast cancer detection for mammography. While Transpara focuses exclusively on breast imaging with advanced features like temporal comparison and risk categorization, DeepHealth offers a broader suite of AI solutions across multiple modalities and disease areas, including prostate, lung, neuroimaging, and thyroid analysis, in addition to breast cancer detection. Therefore, Transpara would be a strong choice for specialized breast imaging needs, whereas DeepHealth might be preferred by organizations seeking a more comprehensive AI platform for various radiological applications.

Choose Transpara if…

Choose Transpara if your primary focus is enhancing breast cancer detection and optimizing radiologist workflow specifically for 2D and 3D mammography. Its temporal comparison feature, analyzing current studies against up to three prior exams over six years, makes it ideal for longitudinal breast cancer screening programs. Additionally, its high negative predictive value for low-risk cases (99.97%) can significantly reduce radiologist workload by confidently triaging cases.

View Transpara →

Choose DeepHealth if…

Choose DeepHealth if your organization requires a comprehensive AI-powered health informatics solution across multiple imaging modalities and disease areas, beyond just breast cancer. Its suites for prostate, lung, neuroimaging, and thyroid analysis, alongside its breast cancer detection capabilities, make it suitable for institutions seeking a unified AI platform for diverse diagnostic needs. The cloud-native or hybrid deployment options and remote scanning/collaboration platform also cater to organizations prioritizing flexible infrastructure and collaborative workflows.

View DeepHealth →

When considering AI tools for radiology, Transpara and DeepHealth offer distinct strengths. Transpara, from ScreenPoint Medical, is highly specialized in breast imaging, providing AI-powered detection for both 2D and 3D mammography. Its key features include temporal comparison, breast density assessment, and risk categorization, making it ideal for practices focused on comprehensive breast cancer screening and diagnosis. Transpara emphasizes workflow optimization and boasts a high negative predictive value for low-risk cases, aiming to enhance radiologist efficiency and confidence in breast imaging interpretation.

DeepHealth, a RadNet subsidiary, presents a broader AI platform, extending beyond breast imaging to include solutions for prostate, lung, neuroimaging, and thyroid nodule detection. While it offers AI-powered breast cancer detection (Breast Suite, Saige-Dx™), its core strength lies in its multi-modality capabilities and a cloud-native operating system (DeepHealth OS) that supports a wider range of diagnostic areas.

The practical difference lies in their scope: Transpara is a deep dive into breast imaging, whereas DeepHealth is a broader platform covering multiple specialties. Physicians whose primary need is to enhance breast cancer detection and streamline mammography workflows would likely find Transpara more tailored to their specific requirements. Conversely, practices seeking a more comprehensive AI solution across various imaging modalities and disease areas, or those looking for a cloud-native platform with remote collaboration features, might find DeepHealth to be the more versatile choice.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Transpara	DeepHealth
Pricing	Unknown	Contact for pricing
Deployment	Transpara integrates into PACS and reading workflows via medical-imaging (DICOM) pipelines. It is also available through Precision Imaging Network, part of Microsoft for Healthcare, which simplifies deployment pathways for cloud-enabled access within existing clinical ecosystems.	Cloud-native or hybrid platform
BAA Available	Unknown	Yes AI-estimated
FDA Status	Cleared AI-estimated	1 AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

DeepHealth

DeepHealth emphasizes a cloud-native operating system (DeepHealth OS) that unifies data and offers personalized, AI-powered workspaces, aiming to simplify deployment and management for IT professionals and provide location flexibility for radiologists.. Transpara integrates into existing PACS and reading workflows, and user feedback indicates seamless integration and improved workflow. However, DeepHealth's broader cloud-native platform and unified environment across multiple solutions suggest a more comprehensive and flexible approach to usability across various roles and locations.

Clinical Value

Transpara

Transpara has a strong emphasis on clinical validation, being the first and only breast AI to be studied in a randomized controlled trial (MASAI trial), which showed a 29% increase in cancer detection and a 44% workload reduction.. While DeepHealth also highlights clinical impact with a 21% increase in breast cancer detection rate in a large real-world analysis, and FDA clearances across multiple clinical areas, Transpara's randomized controlled trial evidence provides a higher level of clinical rigor.

Pricing & Value

Tie

DeepHealth states 'contact for pricing,' indicating a lack of public pricing transparency. Transpara does not provide public pricing information either, requiring direct contact for quotes. Without transparent pricing for either tool, it is impossible to definitively compare their value propositions.

Enterprise Readiness

DeepHealth

DeepHealth offers a cloud-native or hybrid platform with a unified operating system (DeepHealth OS) designed for simplified deployment, operations, security, and infrastructure management, making it highly scalable and adaptable for large enterprises.. DeepHealth also boasts a larger customer base with nearly 3,000 accounts and over 17 million procedures managed during a quarter, indicating significant enterprise adoption and capability. Transpara is deployed in over 30 countries and has analyzed over 13 million mammograms, but DeepHealth's broader platform and customer numbers suggest a stronger enterprise readiness.

Innovation

DeepHealth

DeepHealth demonstrates broader innovation by offering AI-powered solutions across multiple modalities and disease areas, including breast, prostate, lung, neuroimaging, and thyroid, all unified under their DeepHealth OS.. They also integrate 140+ AI algorithms from 75+ vendors into their AI Studio. Transpara focuses specifically on breast cancer detection with features like temporal comparison and breast density assessment. While Transpara is innovative in its niche, DeepHealth's wider scope and platform approach suggest a more expansive innovation strategy.

Support & Docs

Tie

Both companies offer documentation and support. Transpara provides documentation, a knowledge base, and direct contact options for support.. DeepHealth, as a subsidiary of RadNet, likely benefits from established enterprise-level support structures, but specific details on their documentation and support channels are less explicit in the provided information. Without more detailed comparative information on the quality and accessibility of support and documentation for both tools, it is difficult to declare a definitive winner.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Transpara	DeepHealth
Company	ScreenPoint Medical	RadNet, Inc.
Tagline	Earlier detection, enhanced workflow. Detect more breast cancer, efficiently and effectively, with the industry-leading artificial intelligence for 2D and 3D mammograms.	Empowering breakthroughs in care through imaging.
Key Modalities/Disease Areas	2D and 3D mammography (FFDM and DBT) for breast cancer detection	Breast cancer, prostate cancer, lung nodule detection, neuroimaging analysis for neurodegenerative changes, thyroid nodule detection, radiology reporting
Core Functionality	AI-powered detection for 2D and 3D mammograms, Temporal Comparison, Breast Density assessment, Risk categorization, Region-based and overall exam scores, Workflow optimization and workload reduction, Concurrent reading aid, High negative predictive value for low-risk cases (99.97%)	AI-powered detection for breast, prostate, lung, neuroimaging, and thyroid; AI-powered radiology reporting; Cloud-native operating system (DeepHealth OS); Remote scanning and collaboration platform (TechLive™)
Customer Count/Reach	Deployed in over 30 countries, used to analyze over 13 million mammograms worldwide, used in over 200 clinics in 25+ countries.	Thousands of imaging centers and radiology departments around the world use DeepHealth solutions.
Headquarters	Nijmegen, Netherlands	Not specified
API Available	yes	Not specified

Videos

Demos, reviews, and walkthroughs featuring Transpara and DeepHealth.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing radiology workflows and EHR systems?

Transpara integrates into PACS and reading workflows via medical-imaging (DICOM) pipelines and is also available through Microsoft for Healthcare's Precision Imaging Network, simplifying cloud-enabled access within existing clinical ecosystems. DeepHealth offers a cloud-native or hybrid platform with its DeepHealth OS, which unifies data across clinical and operational workflows. DeepHealth also offers Reporting Pro, which integrates clinical AI findings and measurements from DeepHealth and third-party AI tools directly into the reporting workflow, streamlining the creation of structured reports.

What are the key differences in accuracy and sensitivity for breast cancer detection?

Transpara has demonstrated increased cancer detection by 29% and reduced workload by 44% in a randomized controlled trial, with a high negative predictive value of 99.97% for low-risk cases. DeepHealth's Breast Suite applications enabled a 21% increase in breast cancer detection rate in a large-scale real-world analysis, with consistent benefits across dense-breast and diverse patient populations, including 23% more cancers detected in women with dense breasts.

Beyond breast imaging, what other specialties or modalities do these tools support?

Transpara is specifically focused on breast imaging, enhancing detection and optimizing workflow for 2D and 3D mammography. DeepHealth, in addition to AI-powered breast cancer detection, offers solutions for prostate cancer detection, lung nodule detection and reporting, neuroimaging analysis for neurodegenerative changes, and thyroid nodule detection and reporting.

What is the learning curve like for radiologists adopting these AI tools?

Transpara is designed to be a concurrent reading aid, helping radiologists focus on suspicious areas and potentially reducing reading time without compromising accuracy. DeepHealth's solutions, particularly with Reporting Pro, aim to streamline the reporting process by providing AI-generated drafts and integrating findings, allowing radiologists to focus on refinement rather than manual documentation.

What audit-trail features are available to track AI's contribution to diagnoses?

Transpara provides region-based and overall exam scores, categorizing exams by risk (Elevated, Intermediate, Low) and highlighting areas of suspicion, which can be used as decision support. DeepHealth's Reporting Pro integrates clinical AI findings and measurements directly into structured reports, which suggests a clear record of AI's input in the diagnostic process.

How do these tools handle multi-site rollouts and standardization of care?

Transpara is deployed in over 30 countries and has processed over 13 million mammograms, indicating its capability for widespread implementation and consistent performance across various sites. DeepHealth's Breast Suite aims to standardize breast cancer care across screening and diagnostic workflows and has been validated in large-scale real-world analyses across numerous imaging sites.

Can these tools leverage prior imaging studies for improved detection?

Transpara offers Temporal Comparison, which analyzes the current study against up to three prior mammograms over six years to increase sensitivity and specificity by evaluating changes over time. DeepHealth's Mammo Dx can incorporate prior exams into its AI-powered cancer detection workflow, enabling comparison of breast tissue over time to help radiologists identify subtle changes.